ScholarIQanswers from OpenAlex
CTO Andrea Alesini
InstitutionResearch output, impact & collaborations
CTO Andrea Alesini is a institution indexed in ScholarIQ from OpenAlex.
What is known about CTO Andrea Alesini?
ScholarIQrecord summary
CTO Andrea Alesini is a research organisation in Rome, IT. OpenAlex records 3,311 works and 156,666 citations for it. 874 researchers list it as their most recent affiliation.
How many works does CTO Andrea Alesini have?
ScholarIQindexed works
CTO Andrea Alesini has 3,311 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does CTO Andrea Alesini have?
ScholarIQcitation count
CTO Andrea Alesini has 156,666 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at CTO Andrea Alesini?
ScholarIQresearcher count
CTO Andrea Alesini has 874 researchers in the ScholarIQ index.
What is the average h-index at CTO Andrea Alesini?
ScholarIQavg h-index
CTO Andrea Alesini has an average h-index of 53.6 in OpenAlex.
What is the ROR of CTO Andrea Alesini?
ScholarIQror
The ROR for CTO Andrea Alesini is on the source record.
What is the OpenAlex record for CTO Andrea Alesini?
ScholarIQopenalex
The OpenAlex for CTO Andrea Alesini is on the source record.
Who are the most-cited researchers behind CTO Andrea Alesini?
ScholarIQtop researchers by citations
What are the most-cited papers on CTO Andrea Alesini?
ScholarIQmost cited works
Fractional Flow Reserve–Guided PCI versus Medical Therapy in Stable Coronary Disease
Bernard De Bruyne, Nico H.J. Pijls, Bindu Kalesan, Emanuele Barbato, Pim A.L. Tonino, Zsolt Piróth, Nikola Jagić, Sven Möbius‐Winkler, Gilles Rioufol, Nils Witt, Petr Kala, Philip MacCarthy, Thomas Engström, Keith G. Oldroyd, Kreton Mavromatis, Ganesh Manoharan, Peter VerLee, Ole Fröbert, Nick Curzen, Jane B. Johnson, Peter Jüni, William F. Fearon
Gastroenteropancreatic neuroendocrine tumours
Irvin M. Modlin, Kjell Öberg, Daniel C. Chung, Robert T. Jensen, Wouter W. de Herder, Rajesh V. Thakker, Martyn Caplin, Gianfranco Delle Fave, Gregory Kaltsas, Eric P. Krenning, Steven F. Moss, Ola Nilsson, Guido Rindi, Ramón Salazar, Philippe Ruszniewski, Anders Sundin
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
James C. Yao, Nicola Fazio, Simron Singh, Roberto Buzzoni, Carlo Carnaghi, Edward M. Wolin, Jiří Tomášek, Markus Raderer, Harald Lahner, Maurizio Voi, Lida Pacaud, Nicolas Rouyrre, Carolin Sachs, Juan W. Valle, Gianfranco Delle Fave, Eric Van Cutsem, Margot Tesselaar, Yasuhiro Shimada, Do‐Youn Oh, Jonathan Strosberg, Matthew H. Kulke, Marianne Pavel
Fractional Flow Reserve–Guided PCI for Stable Coronary Artery Disease
Bernard De Bruyne, William F. Fearon, Nico H.J. Pijls, Emanuele Barbato, Pim A.L. Tonino, Zsolt Piróth, Nikola Jagić, Sven Mobius-Winckler, Gilles Rioufol, Nils Witt, Petr Kala, Philip MacCarthy, Thomas Engström, Keith G. Oldroyd, Kreton Mavromatis, Ganesh Manoharan, Peter VerLee, Ole Fröbert, Nick Curzen, Jane B. Johnson, Andreas Limacher, Eveline Nüesch, Peter Jüni
Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study
L. Prompers, Nicolaas C. Schaper, Jan Apelqvist, Michael Edmonds, Edward B. Jude, Dı́dac Mauricio, Luigi Uccioli, V. Urbančič, K. Bakker, P. Holstein, Alexandra Jirkovská, Alberto Piaggesi, Gunnel Ragnarson-Tennvall, Heinrich Reike, Maximilian Spraul, K. Van Acker, J. van Baal, Frits van Merode, Isabel Ferreira, M. Huijberts
How much of the research on CTO Andrea Alesini is open access?
ScholarIQopen access share
75%OPEN ACCESS